search
Back to results

Remote Ischemic PreConditioning (RIPC)

Primary Purpose

Unruptured Cerebral Aneurysm

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Standard Manual Aneroid Sphygmomanometer
Sponsored by
Sebastian Koch
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Unruptured Cerebral Aneurysm focused on measuring brain aneurysm, endovascular repair, ischemic stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A diagnosis of an unruptured brain aneurysm deemed suitable for repair by neuroendovascular techniques involving intraluminal occlusion by detachable platinum coils, stent-assisted coiling, pipeline stent, balloon-assisted coiling, covered stent only, neck-bridge device, re-coiling, or re-treatment of a previously coiled/treated aneurysm. There are no restrictions on adjunctive devices.
  2. Absence of ongoing ischemic symptoms such as transient ischemic attacks, minor strokes, stroke-in-evolution, or clinical evidence of cerebral vasospasm within 2 weeks prior to randomization. (If a CT scan, cerebral angiogram, or other imaging performed during the 2 weeks prior to randomization shows radiological vasospasm deemed by the treating physician to be potentially clinically significant, the subject is excluded).
  3. Male or female with a minimum age of 18 years on the day of enrollment.
  4. Informed consent and availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed Informed Consent Form.

Exclusion Criteria:

  1. Dissecting or mycotic brain aneurysm. Fusiform or atherosclerotic intracerebral aneurysms may be eligible for the trial if endovascular treatment is planned with a goal of exclusion of the aneurysm from the circulation.
  2. Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.
  3. Known history of life-threatening allergic reaction to any medication.
  4. Soft tissue, orthopedic, or vascular injury which, in the judgment of the investigator, would preclude arm ischemic conditioning (e.g. superficial wounds, venous, arterial ulcers, gangrene).
  5. History of peripheral vascular disease or deep vein thrombosis in either arm.
  6. Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
  7. Women who are breastfeeding.
  8. Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.
  9. Pre-morbid (estimated) modified Rankin scale score of greater than 2. A subject is not excluded if they have a pre-morbid modified Rankin scale of greater than 2 but the disability does not interfere with the subject's ability to complete an MRI and the cognitive evaluations.
  10. Previous serious traumatic brain injury that would preclude the patient from completing the protocol or preclude MRI analysis of small strokes.
  11. Patients with peripherally inserted central catheters, hemodialysis shunts, arteriovenous fistulae or grafts in the treatment limb, or lymphedema.
  12. Patients with known Human Immunodeficiency Virus (HIV) infection.
  13. Patients who are unable to have an MRI scan for any reason.
  14. Participation in a clinical trial with an investigational drug within 30 days preceding this study. Previous participation in any clinical trial investigating ischemia following endovascular aneurysm treatment, participation in another trial involving RIPC, or prior receipt of RIPC.
  15. Severe or unstable concomitant condition disease or chronic condition, which, in the opinion of the investigator, could affect assessment of the safety or efficacy of study intervention.
  16. Any other medical condition that the site investigator deems would put the patient at excessive risk of participation in the study or an expected life expectancy less than 1 year or that would result in inability to collect clinical outcomes at 30 days.
  17. Systolic blood pressure above 200mm Hg.
  18. Cannot tolerate inflation of the tourniquet on their arm consistent with blood pressure cuff.

Sites / Locations

  • Jackson Memorial Hospital
  • University of Miami

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Treatment group: standard blood pressure cuff

Sham group: standard blood pressure cuff

Arm Description

A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.

The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.

Outcomes

Primary Outcome Measures

Incidence of all adverse events and serious adverse events.
Adverse events are all conditions/symptoms/findings and all abnormal clinically significant laboratory tests both expected and unexpected, occurring from onset of the intervention until study completion.
Change in procedurally-induced vascular cognitive impairment.
As measured by the NIH-toolbox for neurocognitive testing.NIH-Toolbox normalized scores to define a single cognitive battery index.C. Score:0= No deficit, no change; 400= Maximum deficit.

Secondary Outcome Measures

Change in procedurally-induced vascular cognitive impairment.
As measured by the NIH-toolbox for neurocognitive testing. NIH-Toolbox normalized scores to define a single cognitive battery index.C. Score:0= No deficit, no change; 400= Maximum deficit
Volume of embolic strokes by Diffusion Weighted Imaging (DWI).
Measured in select patients by Diffusion Weighted Imaging (DWI) via Magnetic Resonance Imaging (MRI) that undergo 4 cycles of 5 minutes of limb ischemia followed by 5 minutes reperfusion.
Volume of embolic strokes by Fluid-attenuated Inversion Recovery (FLAIR).
Measured in select patients by Fluid-attenuated Inversion Recovery (FLAIR) via Magnetic Resonance Imaging (MRI) that undergo 4 cycles of 5 minutes of limb ischemia followed by 5 minutes reperfusion.
Frequency of large (>10 cc value) strokes.
As measured by MRI imaging when performed.

Full Information

First Posted
January 16, 2019
Last Updated
April 3, 2023
Sponsor
Sebastian Koch
search

1. Study Identification

Unique Protocol Identification Number
NCT03814850
Brief Title
Remote Ischemic PreConditioning (RIPC)
Official Title
Remote Ischemic PreConditioning Provides Neuroprotection: A Phase 2, Single Center, Randomized, Double-Blind, Sham-Controlled, Safety and Efficacy Study Evaluating the Use of Remote Ischemic Preconditioning in Patients Undergoing Endovascular Repair of Brain Aneurysms
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 1, 2023 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Sebastian Koch

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to learn about protecting the brain from low blood flow (ischemia) with limb preconditioning. From human studies the investigators know that the brain can be protected from dangerous low blood flow by reducing the blood flow to an arm or leg for just a short period of time. This is called limb preconditioning. The investigators are studying the safety and feasibility of preconditioning and their effect of protecting the brain from ischemia in two different groups. This is a Phase 2, randomized, double-blind, sham-controlled, design. Up to 50 male and female patients undergoing elective endovascular repair of unruptured brain aneurysm who are randomized to the remote ischemic preconditioned or sham group will be enrolled. This study consists of one 3-9 month study period for each patient plus up to 14 days for enrollment activities. Subjects are required to return between 3-9 months for end-of-study procedures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unruptured Cerebral Aneurysm
Keywords
brain aneurysm, endovascular repair, ischemic stroke

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The person performing the RIPC is not blinded.
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment group: standard blood pressure cuff
Arm Type
Experimental
Arm Description
A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
Arm Title
Sham group: standard blood pressure cuff
Arm Type
Sham Comparator
Arm Description
The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
Intervention Type
Device
Intervention Name(s)
Standard Manual Aneroid Sphygmomanometer
Intervention Description
Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
Primary Outcome Measure Information:
Title
Incidence of all adverse events and serious adverse events.
Description
Adverse events are all conditions/symptoms/findings and all abnormal clinically significant laboratory tests both expected and unexpected, occurring from onset of the intervention until study completion.
Time Frame
9 months
Title
Change in procedurally-induced vascular cognitive impairment.
Description
As measured by the NIH-toolbox for neurocognitive testing.NIH-Toolbox normalized scores to define a single cognitive battery index.C. Score:0= No deficit, no change; 400= Maximum deficit.
Time Frame
Baseline, Day 2-4
Secondary Outcome Measure Information:
Title
Change in procedurally-induced vascular cognitive impairment.
Description
As measured by the NIH-toolbox for neurocognitive testing. NIH-Toolbox normalized scores to define a single cognitive battery index.C. Score:0= No deficit, no change; 400= Maximum deficit
Time Frame
Baseline, 3-9 months.
Title
Volume of embolic strokes by Diffusion Weighted Imaging (DWI).
Description
Measured in select patients by Diffusion Weighted Imaging (DWI) via Magnetic Resonance Imaging (MRI) that undergo 4 cycles of 5 minutes of limb ischemia followed by 5 minutes reperfusion.
Time Frame
Timeframe: Baseline, 12-96 hours post procedures
Title
Volume of embolic strokes by Fluid-attenuated Inversion Recovery (FLAIR).
Description
Measured in select patients by Fluid-attenuated Inversion Recovery (FLAIR) via Magnetic Resonance Imaging (MRI) that undergo 4 cycles of 5 minutes of limb ischemia followed by 5 minutes reperfusion.
Time Frame
Timeframe: Baseline, 12-96 hours post procedures.
Title
Frequency of large (>10 cc value) strokes.
Description
As measured by MRI imaging when performed.
Time Frame
2-4 days post procedures.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of an unruptured brain aneurysm deemed suitable for repair by neuroendovascular techniques involving intraluminal occlusion by detachable platinum coils, stent-assisted coiling, pipeline stent, balloon-assisted coiling, covered stent only, neck-bridge device, re-coiling, or re-treatment of a previously coiled/treated aneurysm. There are no restrictions on adjunctive devices. Absence of ongoing ischemic symptoms such as transient ischemic attacks, minor strokes, stroke-in-evolution, or clinical evidence of cerebral vasospasm within 2 weeks prior to randomization. (If a CT scan, cerebral angiogram, or other imaging performed during the 2 weeks prior to randomization shows radiological vasospasm deemed by the treating physician to be potentially clinically significant, the subject is excluded). Male or female with a minimum age of 18 years on the day of enrollment. Informed consent and availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed Informed Consent Form. Exclusion Criteria: Dissecting or mycotic brain aneurysm. Fusiform or atherosclerotic intracerebral aneurysms may be eligible for the trial if endovascular treatment is planned with a goal of exclusion of the aneurysm from the circulation. Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment. Known history of life-threatening allergic reaction to any medication. Soft tissue, orthopedic, or vascular injury which, in the judgment of the investigator, would preclude arm ischemic conditioning (e.g. superficial wounds, venous, arterial ulcers, gangrene). History of peripheral vascular disease or deep vein thrombosis in either arm. Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test. Women who are breastfeeding. Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol. Pre-morbid (estimated) modified Rankin scale score of greater than 2. A subject is not excluded if they have a pre-morbid modified Rankin scale of greater than 2 but the disability does not interfere with the subject's ability to complete an MRI and the cognitive evaluations. Previous serious traumatic brain injury that would preclude the patient from completing the protocol or preclude MRI analysis of small strokes. Patients with peripherally inserted central catheters, hemodialysis shunts, arteriovenous fistulae or grafts in the treatment limb, or lymphedema. Patients with known Human Immunodeficiency Virus (HIV) infection. Patients who are unable to have an MRI scan for any reason. Participation in a clinical trial with an investigational drug within 30 days preceding this study. Previous participation in any clinical trial investigating ischemia following endovascular aneurysm treatment, participation in another trial involving RIPC, or prior receipt of RIPC. Severe or unstable concomitant condition disease or chronic condition, which, in the opinion of the investigator, could affect assessment of the safety or efficacy of study intervention. Any other medical condition that the site investigator deems would put the patient at excessive risk of participation in the study or an expected life expectancy less than 1 year or that would result in inability to collect clinical outcomes at 30 days. Systolic blood pressure above 200mm Hg. Cannot tolerate inflation of the tourniquet on their arm consistent with blood pressure cuff.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Starke, M.D.
Phone
305-355-1101
Email
RStarke@med.miami.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Sebastian Koch, MD
Phone
305 243-6732
Email
skoch@med.miami.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Starke, M.D.
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sebastian Koch, MD
Organizational Affiliation
University of Miami
Official's Role
Study Director
Facility Information:
Facility Name
Jackson Memorial Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anabela M Cieslicki
Phone
305-243-8044
Email
axc1623@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Robert Starke, M.D.
Phone
305-355-1101
Email
RStarke@med.miami.edu
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anabela M Cieslicki
Phone
305-243-8044
Email
axc1623@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Robert Starke, M.D.
Phone
305-355-1101
Email
RStarke@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Robert Starke, M.D.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Remote Ischemic PreConditioning (RIPC)

We'll reach out to this number within 24 hrs